Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce
Pivotal Plans In The Works
Executive Summary
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
You may also be interested in...
Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
Boehringer Ingelheim's head of innovation Michel Pairet tells Scrip that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss
Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.